B16F0, B16F1, B16F10 (ATCC), ΔBraf/Pten−/− (derived from B6.Cg-Braftm1MmcmPtentm1HwuTg(Tyr-cre/ERT2)13Bos/BosJ mice (UNC-Chapel Hill Mouse Phase 1 Unit)) cell lines PBT2460 and PBT2130 (Drs. W. Kim and J. Bear, UNC-Chapel Hill), and human melanoma cell lines WM1158, SBCl2, Sk-Mel-119, Sk-Mel-173, and WM2664 (Dr. J. Shields, UNC-Chapel Hill) were maintained in DMEM with 4.5 g/mL D-Glucose and 10% FBS. Human melanoma cell lines RPMI7951, RPMI8322, and Mel505 (Dr. J Shields, UNC-Chapel Hill) were maintained in RPMI with 10% FBS. The normal human melanocyte line NHM7 (Dr. J Shields, UNC-Chapel Hill) was maintained in Media 254 (Gibco) supplemented with HGMS (Gibco). EC (isolated by us previously 8 (link)) were maintained in Endothelial Cell Media (EC-Media), composed of DMEM with 1g/L glucose, 5 μg/L bFGF, 10 μg/L VEGF, 100 mg/L heparin, antibiotics, and 10% NuSerum IV (BD).
Protocol detail
Diverse Melanoma and Endothelial Cell Lines
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Antibiotics
Bear
Cell lines
Endothelial cell
Ert2
Glucose
Heparin
Human
Melanocyte
Melanoma
Mouse
Pten
Vegf
Corresponding Organization :
Other organizations : University of North Carolina at Chapel Hill, The University of Texas Southwestern Medical Center, Boston Children's Hospital
Top 5 similar protocols
Variable analysis
independent variables
- Cell lines: B16F0, B16F1, B16F10 (ATCC), ΔBraf/Pten−/− (derived from B6.Cg-Braftm1MmcmPtentm1HwuTg(Tyr-cre/ERT2)13Bos/BosJ mice (UNC-Chapel Hill Mouse Phase 1 Unit)), PBT2460 and PBT2130 (Drs. W. Kim and J. Bear, UNC-Chapel Hill), WM1158, SBCl2, Sk-Mel-119, Sk-Mel-173, WM2664 (Dr. J. Shields, UNC-Chapel Hill), RPMI7951, RPMI8322, Mel505 (Dr. J Shields, UNC-Chapel Hill), NHM7 (Dr. J Shields, UNC-Chapel Hill), and EC (isolated by authors previously)
- Not explicitly mentioned
- Culture medium: DMEM with 4.5 g/mL D-Glucose and 10% FBS for most cell lines, RPMI with 10% FBS for RPMI7951, RPMI8322, and Mel505, Media 254 (Gibco) supplemented with HGMS (Gibco) for NHM7, and Endothelial Cell Media (EC-Media) composed of DMEM with 1g/L glucose, 5 μg/L bFGF, 10 μg/L VEGF, 100 mg/L heparin, antibiotics, and 10% NuSerum IV (BD) for EC
- Positive control: Not explicitly mentioned
- Negative control: Not explicitly mentioned
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!